HURA — TuHURA Biosciences, Inc./NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1498382 ·
Last close
$2.09
Market Cap
$133.19M
52W High
$3.43
52W Low
$0.41
ADV30
209,629
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,763,284 | -9,223,298 | 31,746,253 | 995,977 | 13,245,793 |
| Mar 2026 | 0 | — | -7,529,899 | -7,536,598 | 29,704,779 | 6,298,127 | 6,514,898 |
| Dec 2025 | 0 | — | -4,380,165 | -6,761,316 | 27,353,156 | 3,619,949 | 6,420,828 |
| Sep 2025 | 0 | — | -6,591,304 | -7,102,455 | 25,697,048 | 2,697,416 | 8,919,089 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,303,681
Investing CF
$-233,160
Financing CF
$27,615,137
CapEx
$-124,929
Dividends Paid
$-8,356
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-148,723,589
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-30,270,947
Pretax Income TTM
$-30,924,204
Interest Exp TTM
$653,257
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,289,239 | -30,051,977 | 27,353,156 | 6,420,828 | 20,932,328 | -27,629,150 |
| Dec 2024 | 0 | -17,151,525 | -21,682,306 | 19,966,684 | 5,372,708 | 14,593,976 | -14,728,138 |
| Dec 2023 | 0 | -13,170,156 | -29,316,826 | 4,361,791 | 5,920,537 | -1,558,746 | -11,950,856 |
| Dec 2022 | 0 | -9,718,934 | -9,367,513 | 15,196,608 | 2,892,667 | 12,303,941 | -7,508,259 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $133.84M | $6.92 | — |
| SMNR | Semnur Pharmaceuticals, Inc. | $132.37M | $0.57 | — |
| SPRB | SPRUCE BIOSCIENCES, INC. | $136.54M | $47.51 | — |
| IMUX | IMMUNIC, INC. | $129.76M | $9.51 | — |
| UNCY | Unicycive Therapeutics, Inc. | $127.10M | $4.64 | — |
News headlines (Yahoo Finance, 1h cache)
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related
2026-09-14 11:45 · Yahoo
HURA: Milestone Progression Over Next 12 Months
2026-08-26 09:12 · Yahoo
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
2026-08-14 15:05 · Yahoo
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
2026-07-22 11:40 · Yahoo
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
2026-06-15 11:45 · Yahoo
HURA: Refining TBS-2025 Development Plan
2026-05-26 15:22 · Yahoo
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-15 21:00 · Yahoo
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-12 11:30 · Yahoo
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?
2026-04-20 14:14 · Yahoo
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
2026-04-01 11:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.